NIH blueprint neurotherapeutics network (BPN) medicinal chemistry support program (mcsp)
Ended Awarded Last action
- Contract number
- 75N95020F00001
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $251,981
Award facts
- Contract value 100% obligated
- $251,980.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$18,164 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $270,145 |
About this award
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a delivery order to Curia Global Inc. (doing business as Amri) under the NIH Blueprint Neurotherapeutics Network Medicinal Chemistry Support Program. This $251,980.55 cost-plus-fixed-fee delivery order, awarded on February 24, 2020, with an ultimate completion date of September 1, 2021, provides medicinal chemistry support services for therapeutic development conducted at the contractor's Albany, New York facility. The award includes no small business set-aside designation. This action represents an administrative de-obligation of unexpended and expiring fiscal year 2020 funding in preparation for the September 30, 2025 closing of the period of availability for these appropriated funds, in accordance with 31 U.S.C. Section 1552(a).
Curia Global Inc. is a leading contract development and manufacturing organization specializing in comprehensive pharmaceutical research and development services across the NIH portfolio. The company's expertise encompasses medicinal chemistry, hit-to-lead chemistry, chemical development, analytical testing, process chemistry, scale-up synthesis, and good manufacturing practices production—capabilities directly relevant to the therapeutic development mission of this award. As an established federal contractor registered in SAM.gov since 2003, Curia Global has demonstrated consistent success in securing delivery orders and purchase orders from multiple NIH institutes and centers, including NIDA, the National Institute of Neurological Disorders and Stroke, and the National Center for Advancing Translational Sciences, supporting drug discovery efforts across therapeutic areas including neurology, pain management, and substance abuse.
Quick answers
Who was awarded contract 75N95020F00001?
75N95020F00001 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on February 24, 2020.
How much is contract 75N95020F00001 worth?
The government has obligated $251,981 on 75N95020F00001.
Is contract 75N95020F00001 an order under another contract?
Yes. 75N95020F00001 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95020F00001 competed?
The extent of competition for 75N95020F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award